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Bile acids are synthesized from cholesterol in the
liver and further metabolized by the gut microbiota
into secondary bile acids. Bile acid synthesis is under
negative feedback control through activation of the
nuclear receptor farnesoid X receptor (FXR) in the
ileum and liver. Here we profiled the bile acid compo-
sition throughout the enterohepatic system in germ-
free (GF) and conventionally raised (CONV-R) mice.
We confirmed a dramatic reduction in muricholic
acid, but not cholic acid, levels in CONV-R mice. Re-
derivation of Fxr-deficient mice as GF demonstrated
that the gut microbiota regulated expression of fibro-
blast growth factor 15 in the ileum and cholesterol
7a-hydroxylase (CYP7A1) in the liver by FXR-depen-
dent mechanisms. Importantly, we identified tauro-
conjugated beta- and alpha-muricholic acids as
FXR antagonists. These studies suggest that the
gut microbiota not only regulates secondary bile
acid metabolism but also inhibits bile acid synthesis
in the liver by alleviating FXR inhibition in the ileum.
INTRODUCTION
Bile acids are produced in hepatocytes, stored in the gall-
bladder, and released into the duodenum upon ingestion of
a meal to facilitate absorption of triglycerides, cholesterol, and
lipid-soluble vitamins (Li-Hawkins et al., 2002; Mataki et al.,
2007). Bile acids are efficiently reabsorbed (>95%) from the
intestine, mainly by active transport mediated by the ileal bile
acid transporter (IBAT; also known as ASBT or SLC10A2) but
also through passive diffusion in the upper small intestine and
colon (Chiang, 2009). This efficient enterohepatic circulation of
bile acids is maintained through a tight negative feedback
control of their synthesis. Bile acids function as signaling mole-
cules that not only regulate their own biosynthesis but alsoCell Mmodulate key metabolic pathways involved in lipoprotein,
glucose, drug, and energy metabolism by activation of nuclear
receptors such as farnesoid X receptor (FXR) and the G
protein-coupled receptor TGR5 (Hylemon et al., 2009; Thomas
et al., 2008).
Bile acids are synthesized from cholesterol by a process that
requires the concerted actions of at least 14 liver enzymes
(Chiang, 2009; Russell, 2009). Humans synthesize cholic acid
(CA) and chenodeoxycholic acid (CDCA), whereas mice synthe-
size CA and b-muricholic acid (bMCA) (Russell, 2003). Bile acids
are thereafter conjugated to glycine (predominant in humans) or
taurine (predominant in mice) (Claus et al., 2011). The rate-
limiting enzyme cholesterol 7a-hydroxylase (CYP7A1) initiates
the classic pathway for bile acid synthesis, and CYP27A1 initi-
ates the alternative pathway (Chiang, 2009). Sterol 12a-hydrox-
ylase (CYP8B1) is required for CA synthesis (Li-Hawkins et al.,
2002), whereas the enzyme(s) that catalyze 6- and 7-hydroxyl-
ations to produce bMCA are not yet characterized. Hepatic
expression of CYP7A1 and CYP8B1 is regulated by FXR, which
is highly expressed in both the ileum and liver (Sinal et al., 2000).
Although both CYP7A1 and CYP8B1 can be regulated by
hepatic FXR activation through the nuclear receptors small
heterodimer partner (SHP) and liver receptor homolog-1 (LRH-
1) (Chiang, 2009), recent data suggest that intestinal FXR regu-
lates hepatic CYP7A1 through a fibroblast growth factor 15
(FGF15)-dependent mechanism (Inagaki et al., 2005; Kim et al.,
2007; Zimmer et al., 2012).
It is well established that the gut microbiota has profound
effects on bile acid metabolism by promoting deconjugation,
dehydrogenation, and dehydroxylation of primary bile acids in
the distal small intestine and colon, thus increasing the chemical
diversity of bile acids (Midtvedt, 1974; Ridlon et al., 2006).
Previous studies in rats have shown that the gut microbiota
reduces the bile acid pool size with its greatest effect on bMCA
rather than CA levels (Wostmann, 1973). However, the molecular
mechanisms for how the gut microbiota suppresses bile acid
synthesis are currently unknown. Here we comprehensively
map the bile acid profiles of conventionally raised (CONV-R)
and germ-free (GF) mice throughout the enterohepatic systemetabolism 17, 225–235, February 5, 2013 ª2013 Elsevier Inc. 225
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Figure 1. The Gut Microbiota Alters the Size
and Composition of the Total Bile Acid Pool
(A) Total amount of bile acids in individual organs/
tissues throughout the enterohepatic circulation
and in the feces and serum of GF and CONV-R
Swiss Webster mice.
(B) Total amount of bile acids in the enterohepatic
system obtained by combination of the values
in (A).
(C) Gallbladder weights of GF and CONV-R mice.
Representative gallbladders are shown (inset).
(D and E) Cholesterol (D) and phospholipids (E) in
bile of GF and CONV-R mice.
(F and G) ALP levels in serum (F) and histology of
the gallbladder (G) in GF and CONV-R mice.
Scale bars represent 20 mm. (GF mice weighed
30.2 ± 0.9 g and CONV-R mice 35.2 ± 0.8 g;
p = 0.0007.) Mean values ± SEM are plotted;
n = 14/group; ap < 0.05, bp < 0.01, cp < 0.001
versus GF, Student’s t test.
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acid metabolism. Rederivation of Fxr-deficient mice as GF
showed that the gut microbiota regulates expression of Fgf15
and Cyp7a1 through this nuclear receptor. Importantly, we iden-
tified MCAs as potent FXR antagonists. We propose that the gut
microbiota modulates bile acid synthesis by changing the bile
acid pool composition and by alleviating FXR inhibition in the
small intestine.
RESULTS
TheGutMicrobiota Influences the Size andComposition
of the Bile Acid Pool throughout the Enterohepatic
System
Analysis of bile acids throughout the enterohepatic system of
GF and CONV-R mice revealed that bile acid levels in the
presence of a gut microbiota were reduced in the gallbladder
and small intestine but increased in the cecum, colon, feces,
and serum (Figure 1A). By combining the amounts measured in226 Cell Metabolism 17, 225–235, February 5, 2013 ª2013 Elsevier Inc.all of the tissues, we showed that the
bile acid pool was reduced by 71% ±
2% in CONV-R mice (Figure 1B). Gall-
bladders from the GF mice had the high-
est bile acid levels of all the tissues
analyzed (Figure 1A) and were signifi-
cantly larger than gallbladders from
CONV-R counterparts (Figure 1C). In
contrast, the levels of cholesterol and
phospholipids were reduced in GF gall-
bladders (Figures 1D and 1E). The larger
size of the gallbladder and altered
composition of bile in GF mice were not
associated with inflammation of the gall-
bladder (Figures 1F and 1G).
To assess how the overall bile acid
composition was affected by the gut
microbiota, we performed principal com-
ponent analysis (PCA) of the bile acidcomposition in each compartment of the enterohepatic system.
The first principal component (PC) explained most of the varia-
tion in each tissue and reached >90% in the cecum and colon
where clustering of samples was especially clear (Figure S1A
available online). Furthermore, the second PC explained almost
all of the remaining variation. The PCA explained somewhat
less of the variation in the serum bile acids (PC1, 58%, and
PC2, 26%; Figure S1A). Further network-based analysis using
qp-graph (Castillo et al., 2011) revealed that all tissues were con-
nected by edges in GF mice while the cecum and colon profiles
formed their own cluster in CONV-R mice (Figure S1B), further
emphasizing the markedly altered composition in these organs.
Taken together, these results demonstrate that the gut micro-
biota affects the bile acid composition in all parts of the entero-
hepatic circulation and the greatest differences between GF and
CONV-R mice are observed in the cecum and colon.
Analysis of individual bile acids revealed that taurine-conju-
gated CA and bMCA (TCA and TbMCA, respectively) were the
most common bile acids in the livers of both GF and CONV-R
Figure 2. Specific Bile Acids in Individual Organs/Tissues throughout the Enterohepatic Circulation and in the Feces and Serum of GF and
CONV-R Swiss Webster Mice
n = 14/group. The bile acid profile in the small intestine shows the combined data from three segments (presented in Figure S2). Mean values ± SEM are plotted.
ap < 0.05, bp < 0.01, cp < 0.001 versus GF, Student’s t test. CA, cholic acid; LCA, lithocholic acid; UDCA, ursodeoxycholic acid; CDCA, chenodeoxycholic acid;
DCA, deoxycholic acid; MCA, muricholic acid; T, taurine-conjugated species. See also Figures S1–S3 and Table S2.
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levels of TbMCA and increased levels of TCA and TaMCA
compared with GF counterparts (Figure 2). TuMCA and TDCA
were exclusively present in CONV-R livers (Figure 2). The bile
acid profile of the gallbladder and the small intestine resembled
that of the liver (Figure 2). Analyses of the individual intestinal
segments revealed that the bile acid profile in CONV-R mice
was dominated by TCA in the proximal intestine and CA in the
distal small intestine (Figure S2), indicating efficient microbial de-
conjugation in the small intestine, which is essential for further
microbial metabolism into secondary bile acids in the colon. In
contrast, small intestines from GF mice almost exclusively con-
tained TbMCA and TCA in addition to low levels of TUDCA
(Figures 2 and S2) confirming that, in contrast to humans (Rus-
sell, 2003), UDCA is a primary bile acid in rodents.
Further microbial modifications of the bile acid pool were
evident in the distal gut of CONV-R mice, which was dominated
by DCA and uMCA and almost depleted of taurine-conjugated
bile acids (Figure 2). In contrast, the bile acid profile in the distal
gut of GF mice was similar to that of the small intestine. As ex-
pected, the bile acid profile of feces in both groups reflected
the profiles in the cecum and colon (Figure 2). The serum bile
acid profile (Figure 2) most closely resembled the bile acids inCell Mthe distal small intestine (Figure S2), which probably reflects
the fact that most bile acids are reabsorbed from the ileum.
By combining the amounts measured in the entire enterohe-
patic system, we showed that the total content of conjugated
and unconjugated metabolites of bMCA was reduced by
71% ± 3% in CONV-R mice whereas the total content of CA
was unchanged (p = 0.75; Figure S3). Accordingly, the reduced
MCA levels explain the lower bile acid pool size in CONV-R
mice (Figure 1B).
The Gut Microbiota Alters the Expression Profile
of Genes Involved in Bile Acid Synthesis, Conjugation,
and Reabsorption
Next we determined whether the altered bile acid profile in
CONV-R mice was associated with microbial regulation of
enzymes in the bile acid synthesis pathway. Expression levels
of most enzymes involved in bile acid synthesis were reduced
in livers of CONV-R mice (Figure 3A). The activity of CYP7A1
(the rate-limiting enzyme in the bile acid synthetic pathway in
the liver) was also reduced in microsomes isolated from livers
of CONV-R mice (Figure 3B). However, the hepatic activity of
CYP8B1 (which is essential for CA production) was not signifi-
cantly affected by the presence of gut microbiota (Figure 3A,B),etabolism 17, 225–235, February 5, 2013 ª2013 Elsevier Inc. 227
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Figure 3. Bacterial Regulation of Genes
Involved in Bile Acid Synthesis, Conjuga-
tion, and Reabsorption
Gene expression of enzymes involved in bile acid
biosynthesis (A), activity of CYP7A1 and CYP8B1
(B), taurine levels (C), and gene expression of
enzymes and transporters involved in taurine
biosynthesis and bile acid conjugation (D) in liver
from GF and CONV-R Swiss Webster mice. Gene
expression of bile acid transporters in the distal
ileum (E) and liver (F) from GF and CONV-R mice.
Mean values ± SEM are plotted; n = 8 mice/group;
ap < 0.05, bp < 0.01, cp < 0.001 versus GF,
Student’s t test.
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Gut Microbiota and Bile Acidsconsistent with the similar CA levels observed in GF and CONV-
R mice (Figure S3).
Newly synthesized bile acids are conjugated with taurine in
a two-step process, an initial step catalyzed by BACS and a
second step requiring BAT (Chiang, 2009). In agreement with
earlier work (Claus et al., 2008), hepatic taurine content was
reduced in CONV-R mice (Figure 3C). Expression of Bacs and
its upstream regulator Hnf4a1 was downregulated in livers
from CONV-R mice but Bat was not affected (Figure 3D). We
also observed increases in the expression of the taurine trans-
porter Taut, the main regulator of intracellular taurine levels,
and Csd, the rate-limiting enzyme for the conversion of cysteine
to taurine, in the livers of CONV-R mice (Figure 3D), which may
indicate an attempt to compensate for the reduced hepatic
taurine content.
After release into the duodenum, bile acids travel the length of
the small intestine and are reabsorbed and transported back to
the livermainly in the distal ileum (Dawson et al., 2009).We deter-
mined the expression of genes involved in bile acid transport and228 Cell Metabolism 17, 225–235, February 5, 2013 ª2013 Elsevier Inc.homeostasis in the distal ileum and liver
(Figures 3E and 3F). We found that
expression of apical bile acid transporters
was downregulated in the ileum of CONV-
R mice, whereas basolateral transporters
were upregulated (Figure 3E). The gut
microbiota had less of an effect on
expression of bile acid transporters in
the liver (Figure 3F).
Microbial-Induced Expression
of Fgf15 in the Ileum Requires
Functional FXR
FXR is known to play a key role in the
regulation of bile acid synthesis and
homeostasis (Sinal et al., 2000), and we
therefore investigated whether the effects
of the gut microbiota on bile acid syn-
thesis are mediated through FXR. We first
showed that the presence of a gut micro-
biota upregulated expression of Fxr and
its molecular targets Shp and Fgf15 in
the distal ileum of CONV-R compared
with GF mice (Figure S4A). In contrast,
the gut microbiota had no effect onexpression of Fxr or its downstream targets Shp and Lrh1 in
the liver (Figure S4B), which suggests that the gut microbiota
regulates the activity of FXR in the ileum but not in the liver.
To directly test the effect of the microbiota on targets down-
stream of FXR, we rederived Fxr/ mice on a C57BL/6 back-
ground as GF. The microbiota-induced expression of Shp and
Fgf15 in the ileum was completely abolished in Fxr-deficient
mice (Figure 4A), demonstrating the requirement for FXR in
mediating these transcriptional responses. It is noteworthy that
the gut microbiota had a more pronounced effect on Fgf15
expression in C57BL/6 mice (Figure 4A) than in Swiss Webster
mice (Figure S4A). Expression of the classical FXR target gene
Ibabp was only slightly increased in the presence of gut
microbiota, but the basal expression in GF mice was completely
abolished in Fxr-deficient mice (Figure 4A). The expression of
Ibat was reduced in colonized mice irrespective of genotype
(Figure 4A).
Expression ofCyp7a1 in the liver was reduced in wild-type but
not Fxr-deficient CONV-R mice (Figure 4B), consistent with the
Fgf15
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Figure 4. Microbial and/or FXR Regulation
of Genes Involved in Feedback Regulation
of Bile Acid Synthesis
(A and B) Expression of genes involved in bile acid
homeostasis in the distal ileum (A) and liver (B) of
wild-type (WT) and Fxr-deficient (Fxr/) mice
raised as CONV-R or GF on a C57BL/6 genetic
background. Mean values ± SEM are plotted;
n = 4–8 mice/group. Expression of each gene is
normalized to that of GFwild-typemice. Data were
analyzed with two-way ANOVA followed by Bon-
ferroni post hoc test: *p < 0.05,**p < 0.01, ***p <
0.001, significant for colonization. ap < 0.05,
bp < 0.01, cp < 0.001, significant for genotype.
#Significant for genotype-colonization interaction.
(GF WT and Fxr/mice weighed 26.7 ± 1.4 g and
25.3 ± 1.3 g, respectively; CONV-R WT and Fxr/
mice weighed 25.0 ± 1.3 g and 25.7 ± 2.4 g,
respectively.)
(C) Gene expression of ileal Fgf15 and hepatic
Cyp7a1 expression in GF and CONV-R C57BL/6
mice treated with vehicle or INT-747 (n = 3–6 mice/
group). Mean values ± SEM are plotted; dp < 0.05,
ep < 0.01 versus control, Mann-Whitney U test.
See also Figures S4–S7 and Table S1.
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Fgf15 in the ileum suppress Cyp7a1 expression in the liver. As
previously described, Shp was suppressed by FXR in the liver
(Sinal et al., 2000), but the regulation was microbiota indepen-
dent (Figure 4B). We also showed that treatment of GF and
CONV-R C57BL/6 mice with the FXR agonist INT-747 increased
ileal Fgf15 expression and suppressed hepatic Cyp7a1 expres-
sion (Figure 4C), thus demonstrating that reduced FXR signaling
in GF mice can be reversed by treatment with a specific FXR
agonist.
In contrast to the clear effects of Fxr genotype on gene expres-
sion, bile acid levels in the gallbladder and small and large intes-
tine appeared to be more dependent on colonization status (Fig-
ure S5). However, we found that the gut microbiota suppressed
serum levels of TCA and TbMCA in an Fxr-dependent fashion
(Figure S5). We also noted increased levels of serum cholesterol
in colonized Fxr-deficient mice (Figure S6A) and liver cholesterol
in colonized mice (Figure S6B). In agreement, we also observed
reductions in Hmgcr and Hmgcs1 expression (Figure S7).
Antibiotic Treatment of CONV-R Mice Modifies Bile Acid
Composition and Expression of Fgf15 and Cyp7a1
To investigate whether microbiota-induced changes in bile acid
composition and Fgf15 and Cyp7a1 expression are reversible in
colonized mice, we treated CONV-R mice with an antibiotic
cocktail consisting of bacitracin, neomycin, and streptomycin,
which are nonabsorbable from the intestine. We showed that
antibiotic treatment increased the levels of TCA and TbMCA inCell Metabolism 17, 225–235the gallbladder of wild-type mice and
reduced levels of secondary bile acids in
serum (Figures 5A and 5B). These results
are in agreement with a recent study
showing increased levels of TCA and
TbMCA in the intestinal lumen of ampi-cillin-treated mice (Kuribayashi et al., 2012). Antibiotic treatment
also promoted a dramatic suppression of Fgf15 expression and
a corresponding increase of Cyp7a1 expression (Figure 5C).
Thus, antibiotic treatment results in a phenotype similar to that
observed in GF mice, namely modified bile acid composition
together with reduced Fgf15 and increased Cyp7a1 expression.
T-MCAs Are FXR Antagonists
It is known that CAs but not MCAs are FXR agonists (Reschly
et al., 2008), and thus the similar levels of CAs observed in small
intestines of GF and CONV-Rmice (Figures 2 and S2) are hard to
reconcile with the higher expression of FXR-dependent genes in
the ileum of CONV-R mice (Figures 4A and S4). However, MCA
levelswere significantly higher in the ileumofGFmice (Figure S2).
MCAs are much less hydrophobic than primary human bile acids
CDCA and CA, which have affinities to FXR directly related to
their hydrophobicity (Reschly et al., 2008). Docking of TbMCA
into the ligand binding pocket of FXR with the FXR 6E-CDCA
(OCA, obeticholic acid; INT-747) cocrystal structure suggested
that, in contrast to the 6a ethyl group of 6E-CDCA, the 6b
hydroxyl group of TbMCA does not occupy the pocket near
Tyr358, Phe363, and Tyr366 (Figure 6A). This pocket is known
to be critical for the activation of FXR (Mi et al., 2003), and led
us to hypothesize that TbMCA may act as an FXR antagonist.
To test our hypothesis, we performed a coactivator recruit-
ment assay and showed that both TaMCA and TbMCA were
FXR antagonists with IC50 values of 28 mM and 40 mM, respec-
tively (Figure 6B). Taurine conjugation was essential for, February 5, 2013 ª2013 Elsevier Inc. 229
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Figure 5. Antibiotic Treatment Modifies Bile Acid Composition and
Regulates Gene Expression
(A and B) Specific bile acid levels in the gallbladder (A) and serum (B) from
CONV-R C57BL/6 mice treated with vehicle or a mixture of bacitracin,
neomycin, and streptomycin.
(C) Fgf15 expression in the ileum (left) andCyp7a1 expression in the liver (right)
from CONV-R mice treated with vehicle or a mixture of bacitracin, neomycin,
and streptomycin.
Mean values ± SEM are plotted; n = 3–8 mice/group; ap < 0.05, bp < 0.01,
cp < 0.001 versus GF, one-way ANOVA. DCA, deoxycholic acid; MCA, mur-
icholic acid; T, taurine-conjugated species.
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Gut Microbiota and Bile Acidsantagonistic activity and, as expected, neither TaMCA nor
TbMCA activated FXR in this assay (data not shown). To exclude
the possibility that the observed antagonistic activity was due to
nonspecific detergent effects at high bile acid concentrations,
we showed that the concentration-response curve for the selec-
tive FXR agonist GW4064 was shifted to the right in the presence
of 100 mM or 400 mM TbMCA (Figure 6C). We next investigated
whether TbMCA could also function as an FXR antagonist in230 Cell Metabolism 17, 225–235, February 5, 2013 ª2013 Elsevier Inthe small intestine, which has been shown to have the highest
Fgf15 expression of all tissues (Larsson et al., 2012). We
treated ileal explants from CONV-R mice with TCA to induce
Fgf15 expression and found that TbMCA prevented this induc-
tion in a concentration-dependent fashion (Figure 6D). In addi-
tion, we induced ileal Fgf15 and Shp expression in GF mice
in vivo by treatment with TCA and showed that simultaneous
treatment with TbMCA significantly reduced this induction
(Figures 6E and 6F). We could not repeat this experiment in
CONV-R mice since the gut microbiota rapidly deconjugates
TbMCA to bMCA. Taken together, these data indicate that
TbMCA is a competitive and reversible antagonist for ligand-
activated FXR.
DISCUSSION
Here we identified a profound role of the gut microbiota not only
on secondary bile acid metabolism but also as regulator of
hepatic bile acid synthesis. In the presence of a gut microbiota,
mice had a smaller bile acid pool, with specific reductions in
MCAs rather than CA. By comparing GF and CONV-R Fxr-
deficient mice, we demonstrated that the gut microbiota regu-
lates Fgf15 in the ileum through a FXR-dependent pathway.
Finally, we identified TaMCA and TbMCA as FXR antagonists,
and thus we propose that the higher levels of MCAs in GF
mice at least partially account for the lower expression of FXR-
dependent genes in the ileum of GF mice.
In the presence of a gut microbiota, bile acid levels were
reduced in the gallbladder and small intestine, in agreement
with earlier observations (Claus et al., 2008; Wostmann, 1973).
By contrast, bile acid levels were higher in the cecum, colon,
and feces of CONV-R mice compared with GF mice. Bile acids
were more chemically diverse in CONV-R mice and the diversity
was greatest in the cecum, colon, and feces of these animals.
Thus, themost obvious microbial effects on the bile acid compo-
sition were in the compartments with the highest number of
bacteria. No secondary bile acids were observed in GF mice.
Our findings thus suggest that the reduced bile acid pool size
in CONV-R mice may also reflect reduced bile acid reabsorption
from the distal ileum and increased bile acid excretion in feces. In
agreement, we showed that expression of Ibat and other trans-
porters were reduced in CONV-R mice compared with their GF
counterparts. Earlier studies have shown that TCA uptake is
increased in ileal epithelium isolated from GF rats and that the
half life of 14C-labeled CA is four to five times longer in GF
compared with CONV-R rats (Gustafsson et al., 1957; Riottot
and Sacquet, 1985), supporting a role for increased reabsorption
of bile acids that may further contribute to the larger bile acid
pool in GF mice (Kellogg and Wostmann, 1969).
We observed a 71% reduction in MCA levels in CONV-R mice
but with no effect on CA levels. CYP8B1 activity, which is
required for CA formation (Li-Hawkins et al., 2002), was not
altered in the presence of gut microbiota. By contrast, both
gene expression and activity of CYP7A1 were reduced in
CONV-R mice, supporting previous studies in rats (Gustafsson
et al., 1975; Swann et al., 2011). CYP7A1 is required for CDCA
formation, which is rapidly converted to MCAs through micro-
somal 6b hydroxylation in rodent livers (Gustafsson et al.,
1975). We could not analyze the expression levels of the 6bc.
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Figure 6. Taurine-Conjugated MCAs Are
Competitive FXR Antagonists
(A) Docking of TbMCA (yellow) in the ligand-
binding pocket of FXR using the FXR 6E-CDCA
cocrystal structure (blue).
(B) Coactivator recruitment assay to assess
whether TaMCA and TbMCA are functional
antagonists to CDCA (80 mM)-mediated activation
of FXR.
(C) Activation of FXR by GW4064 in the presence
of 100 mM and 400 mM TbMCA to demonstrate
reversibility of binding (assays were performed in
triplicate and one out of two independent experi-
ments is presented).
(D) Fgf15 expression in ileal explants treated with
TCA in the presence of different amounts of
TbMCA. The assay was performed in explants
derived from five independent mice.
(E and F) Gene expression of Fgf15 (E) and Shp (F)
in the ileum of GF C57BL/6 mice treated in vivo
with TCA in the absence or presence of TbMCA
(n = 6–7 mice/group).
Data were analyzed with one-way ANOVA fol-
lowed by Bonferroni post hoc test. Mean values ±
SEM are plotted; ap < 0.05, bp < 0.01, cp < 0.001
versus control.
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Gut Microbiota and Bile Acidshydroxylase required for MCA synthesis as it has not yet been
identified; however, 6b hydroxylation is reduced in liver micro-
somes isolated from CONV-R mice and rats compared with GF
counterparts (Claus et al., 2011; Gustafsson et al., 1975).
Together, these changes in enzymatic activity are consistent
with the reduced bMCA/CA ratio observed in CONV-R mice.
FXR is highly expressed in liver and ileum, where it regulates
distinct transcriptional networks (Thomas et al., 2010). It is
generally recognized that FXR negatively regulates bile acid
synthesis directly in the liver by inducing expression of SHP,
which represses LRH-1, leading to reduced transcription of
Cyp7a1 (Chiang, 2009). However, by comparing expression of
direct FXR target genes in the liver (Shp and Lrh1) and ileum
(Shp and Fgf15), we showed that the gut microbiota primarily
affects FXR targets in the ileum and not the liver. Rederivation
of Fxr/ mice as GF confirmed that Fgf15 expression in the
ileum required functional FXR signaling. The absence of estab-
lished assays for FGF15, as noted in recent studies (Kir et al.,
2011; Modica et al., 2012), prevented us from validating these
findings at the protein level, but our data are in agreement with
recent studies that showed an indirect effect of FXR signaling
on bile acid synthesis by increasing expression of Fgf15 in the
ileum (Inagaki et al., 2005; Zimmer et al., 2012). A recent study
demonstrated that FGF19 administration suppressed bile acid
synthesis in Fxr-deficient mice (Miyata et al., 2011), thus further
implying that FGF15/19 are downstream of FXR and directlyCell Metabolism 17, 225–235responsible for Cyp7a1 suppression.
The precise mechanism remains to be
elucidated, but it has been proposed
that FGF15 is transported to the liver
where it binds FGFR4 and acts to
suppress Cyp7a1 (Inagaki et al., 2005;
Zimmer et al., 2012). Tissue-specificknockouts have shown thatCyp7a1, but notCyp8b1, is predom-
inantly regulated by the FXR-FGF15 pathway in mice (Kim et al.,
2007). Rederivation of tissue-specific Fxr-deficient mice as GF
would be useful in future studies to assess the precise contribu-
tion of FXR signaling in the ileum and the liver to the microbiota-
mediated regulation of the FGF15-CYP7A1 pathway. It is known
that GF mice have altered gut physiology (Ba¨ckhed et al., 2005),
which may contribute to the observed changes in gene expres-
sion and bile acid composition. However, we showed that treat-
ment of CONV-R mice with an antibiotic mixture resulted in
modified bile acid composition, suppressed ileal Fgf15 expres-
sion and increased hepatic Cyp7a1 expression. Thus, the
phenotype of antibiotic-treated mice was similar to that of GF
mice, providing further evidence of an important role of the
microbiota in the modulation of bile acid metabolism.
The presence of a gutmicrobiota increases the hydrophobicity
of the bile acid pool and thus generates a bile acid profile that is
a more potent activator of FXR. Importantly, we identified both
TaMCA and TbMCA as FXR antagonists in vitro. TaMCA was
not present in the distal small intestine of GF mice, but the
combined TaMCA and TbMCA levels in the distal small intestine
of CONV-Rmice were 14-fold lower than the TbMCA levels in the
same tissue from GF mice. The lower T-MCA/CA ratio in CONV-
R mice will thus result in increased activity of FXR. Furthermore,
we also showed that TbMCA significantly reduced the TCA-
induced expression of Fgf15 in the ileum ex vivo as well as in, February 5, 2013 ª2013 Elsevier Inc. 231
Figure 7. Model for Microbial Regulation of Bile Acid Metabolism
GF mice have a larger total bile acid pool size compared with their CONV-R counterparts. The activity and expression of CYP7A1 and levels of TbMCA
are increased in GF mice, whereas the expression and activity of CYP8B1 and levels of CA are similar in GF and CONV-R mice. TbMCA functions as a
natural antagonist of FXR, whichmay result in reduced inhibition of CYP7A1 in GFmice. In CONV-Rmice, the reduction in TbMCA leads to increased activation of
FXR in enterocytes, which upregulates FGF15, a potential suppressor of CYP7A1 in the liver. Furthermore, the presence of the gut microbiota in the intestine of
CONV-R mice causes variation in the bile acid profile due to the presence of secondary bile acids, as well as increased excretion of bile acids. Enzymes are
indicated in gray.
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suppress Cyp7a1 and bile acid synthesis by reducing the levels
of T-MCAs and promoting FXR-dependent Fgf15 expression in
the ileum (Figure 7). Furthermore, it predominantly suggests
that the gut microbiota modulates FXR signaling in the gut.
In summary, we have demonstrated that the gut microbiota
has a profound systemic effect on bile acid metabolism. Not
only does the gut microbiota exert its effects within the gut,
but also in other parts of the enterohepatic system, such as regu-
lating bile acid synthesis in the liver. We demonstrate that the
microbial suppression of biosynthetic genes in the liver is consis-
tent with increased FXR-dependent activation of Fgf15 in the
ileum due to reduced levels of TbMCA.
EXPERIMENTAL PROCEDURES
Mice
GF male Swiss Webster and C57BL/6 mice were maintained under a strict
12 hr light cycle in flexible plastic film isolators. Fxr/ mice backcrossed
four generations on to a C57BL/6 backgroundwere obtained from the Jackson
Laboratory through a MTA with Frank Gonzalez and backcrossed four more
generations onto C57BL/6 (backcrossed eight generations in total). The
Fxr/ mice were rederived as GF through embryo transfer and maintained
under a strict 12 hr light cycle in flexible plastic film isolators.
All mice were fed an autoclaved chow diet (Labdiet, St. Louis, MO) ad
libitum. GF isolators were routinely tested for sterility by culturing and PCR
analysis of feces amplifying the 16S rRNA gene.
All mice were aged 9–16 weeks at the time of analysis and were age
matched (±2 weeks) for the individual experiments. Blood was collected
from the inferior vena cava under deep isoflurane-induced anesthesia after
a 4 hr fasting period. Liver, gallbladder, small intestine, cecum, and colon
were harvested, and the small intestine was divided into three equal segments232 Cell Metabolism 17, 225–235, February 5, 2013 ª2013 Elsevier Innumbered in ascending order. A small biopsy from the most distal part of the
small intestine was taken for RNA analysis of ileum. All tissues for bile acid and
RNA analysis were snap frozen in liquid nitrogen and stored in 80C until
further processed. Fecal droppings from each cage were collected.
INT-747 (obeticholic acid, OCA; 6a-ethyl-CDCA) was a kind gift from
Luciano Adorini (Intercept, Corciano, Italy). INT-747 (10 mg/kg body weight
dissolved in 1%methylcellulose) or vehicle (1%methylcellulose) was adminis-
tered to GF and CONV-R C57BL/6 mice by intragastric gavage 2 and 14 hr
before the mice were killed. The antibiotics bacitracin, neomycin, and strepto-
mycin (200 mg/kg body weight/day for each reagent) were administered orally
to CONV-R C57BL/6 mice for 3 days. TCA (Sigma-Aldrich, St Louis, MO) or
amixture of TCA and TbMCA (Steraloids, Newport, RI) (400mg/kg bodyweight
of each compound dissolved in sterile water at a concentration of 40mg/ml) or
vehicle (sterile water) was administered to GF C57BL/6 mice by intragastric
gavage on two occasions (2 and 14 hr before the mice were killed). All
experiments were performed with protocols approved by the University of
Gothenburg Animal Studies Committee.
Analysis of Bile Acids
Reagents
LCA was obtained from Calbiochem (Gibbstown, NJ); UDCA from Fluka
(Buchs, Switzerland), CA, DCA, TCA, TCDCA, TDCA, TLCA, and TUDCA
from Sigma-Aldrich; and aMCA, bMCA, uMCA, TaMCA, and TbMCA from
Steraloids (Newport, RI). The internal standards CA-d4, LCA-d4, UDCA-d4,
CDCA-d4, and DCA-d4 were obtained from Qmx Laboratories (Essex, UK)
and TCDCA-d4, TLCA-d4, TDCA-d4, TUDCA-d4, and TCA-d4 were synthe-
sized at VTT (Tserng et al., 1977).
Sample Preparation for Serum and Tissues
Internal standards (10 ml 100 ppm) and water (240 ml) were added to 40 ml
serum sample and vortexed. Acetonitrile (300 ml) was added to precipitate
proteins. The centrifuged sample was filtrated with Sirocco Protein Precipita-
tion Plate (Waters, Milford, MA), frozen, and evaporated (Savant SpeedVac,
Thermo Fisher Scientific, Walthan, MA). The reconstituted sample was alkal-
ized with 0.5 M NaOH (10 ml) and purified with Oasis HLB LP 96-well platec.
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water; the sample was loaded and washed twice with 300 ml water. Samples
were eluted with 300 ml 90% acetonitrile, frozen, evaporated and reconstituted
with 30% methanol.
Tissues were weighed and internal standards were added before extraction
with 0.2 M NaOH (0.5–6 ml) at 80C for 20 min. After cooling, 1.5–6 ml of water
was added, and the samples were purified from lipids using liquid-liquid
extraction with 1.5–6 ml of hexane. The extraction step was repeated three
times and water phases were combined and the samples were further purified
with Oasis HLB 3 cc 60mg (Waters). The cartridges were conditioned with 1ml
methanol and 3 ml water; 4 ml sample was loaded and washed twice with
500 ml water. Samples were eluted with 1 ml acetonitrile:methanol:water
(4:4:2), frozen, evaporated, and reconstituted with 50% methanol. For taurine
analysis, 20 ml of the aqueous phase was aspirated and 80 ml boric acid buffer,
and 20 ml AccQ,Fluor reagent was added to the extract. The sample mixture
was instantly vortexed for 60 s before analysis. Norvaline was used as an
internal standard for taurine analysis.
UPLC-MS Analysis of Bile Acids
Bile acids were analyzed on an Acquity UPLC system coupled to a Waters
Xevo TQ-S MS (Waters, Manchester, UK) with an Acquity HSS T3 (2.1 3
100 mm, 1.7 mm) column (Waters) and gradient elution with 10 mM formic
acid in water and 10 mM formic acid in acetonitrile:methanol (35:65) as mobile
phases. Cone voltage was 70 V and collision energy 2 eV for unconjugated bile
acids and 90 V and 65 eV for taurine conjugates. Analytes were detected by
selected ionmonitoring and quantified by internal standardmethods. The des-
olvation temperature was 650C, and the source temperature 150C. Selected
reaction monitoring (SRM) was used with dwell times of 32–247 ms. Analytes
were quantified with deuterized internal standards for all analytes except for
MCAs and 7oxo-MCA, for which CA-d4 was used. TCA-d4 was used as
internal standard for all taurine conjugates. Results were calculated as
response (area analyte/area internal std). Retention times of analytes are presented
in Table S2.
UPLC-UV Analysis of Taurine
Taurine was analyzed on an Acquity UPLC system (Waters, Milford, MA) with
a diode array detector, and chromatography was performed with an Acquity
Mass Trak (2.1 3 150 mm, 1.7 mm) column (Waters) kept at 43C. Separation
of 1 ml sample was performed with gradient elution with 10% (v/v) Amino Acid
Analysis Concentrate A in water (A) and Amino Acid Analysis Eluent B (B) at
a flow rate of 0.4 ml/min. Signal was detected at 260 nm (2.4 nm resolution,
20 points/s).
Quantitative Real-Time PCR
Liver or distal ileum (30 mg) was homogenized with TissueLyzer (QIAGEN),
and total RNA was isolated with the RNeasy kit (QIAGEN). The High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used
to synthesize 20 ml cDNA templates from 500 ng purified RNA with random
hexamer primers, and the products were diluted 73 before use in subse-
quent reactions. SYBR Green Master Mix buffer (13; Thermo Scientific)
was used for quantitative real-time PCR at final reaction volumes of 25 ml.
Gene-specific primers (900 nM) were used in each reaction and all results
were normalized to the ribosomal protein L32 mRNA (primer sequences
can be found in Table S3). PCR product specificity was verified by perfor-
mance of a melting curve for each primer set. Assays were performed in a
7900HT Fast Real-Time PCR System (Applied Biosystems) or CFX96 Real-
Time System (Bio-Rad Laboratories). The reactions were analyzed with the
DDCT analysis method.
Enzyme Activity of CYP7A1 and CYP8B1
Microsomes were prepared from each mouse liver by differential ultracentri-
fugation of liver homogenates as described previously (Einarsson et al.,
1986). The activity of CYP7A1 was determined as the formation of 7a-hy-
droxycholesterol (pmol/mg protein/min) from endogenous microsomal
cholesterol at pH 7.4 via isotope dilution mass spectrometry in duplicate
samples from each mouse (Einarsson et al., 1986). CYP8B1 activity was
determined as the formation of 7a, 12a-dihydroxy-4-cholesten-3-one
(pmol/mg/min) from added 7a-hydroxy-4-cholesten-3-one at pH 7.0 with
isotope dilution mass spectrometry in duplicate samples from each mouse
(Andersson et al., 1999).Cell MFXR Coactivator Recruitment Assay
aMCAand bMCAand their respective taurine conjugates were tested for direct
FXR activity in a coactivator recruitment assay as previously described (Solaas
et al., 2004). The ligand binding domain of human FXR (amino acids 222–472)
was expressed in Eschericha coli as an NH2-terminal His-tagged protein
with the pET28a vector (Novagen) and the protein was purified by affinity
chromatography. The activity of recombinant human FXR was determined in
a FXR coactivator recruitment assay in white 384-well plates (Greiner).
Eu3+-coupled anti-His antibody (anti-His-Eu3+) and allophycocyanin-coupled
streptavidin were obtained from PerkinElmer Life Sciences. An N-terminally
biotinylated peptide (NH2-HSSLTERHKILHRLLQEGSPS-COOH) (Innovagen,
Sweden) derived from steroid receptor coactivator 1 was used as coactivator.
A 20 ml reaction volume contained 20 mM Tris (pH 7.5), 0.125% CHAPS,
2 mM dithiotreitol, 0.05% bovine serum albumin, 0.14 mg/ml anti-His-Eu3+,
2.9 mg/ml allophycocyanin-coupled streptavidin, 75 nM human FXR-ligand
binding domain, 150 nM biotinylated steroid receptor coactivator 1 peptide,
and the appropriate ligand. Antagonist activity was measured in the presence
of 80 mM CDCA in the reaction mixture. After addition of all reagents, plates
were incubated for 1 hr at room temperature and time-resolved fluorescence
was measured in a Pherastar platereader (BMG Labtech). Excitation was at
340 nm, and fluorescence was measured at 615 nm and 665 nm. Specific
signals were calculated by dividing the 665 nm signal by the 615 nm signal
and multiplying the fraction by 10,000. TaMCA and TbMCA were purchased
from Steraloids. GW4064 was obtained from AstraZeneca R&D Mo¨lndal and
was used at concentrations ranging from 5.1 nM to 100 mM. XLFit (ID Business
Solutions) was used to fit the experimental data points to curves and to
calculate IC50 values.
Ex Vivo Experiments
CONV-R mice were killed by cervical dislocation, and approximately 1 cm
section of distal ileum was collected. Intestinal contents from the section
were removed through flushing with cold PBS, and the section was divided
into four equal longitudinal parts. Each part was placed in cell culture plates
containing growth medium (Dulbecco’s modified Eagle’s medium with gluta-
mine and pyruvate, 4.5 g/l glucose, 10% fetal calf serum, 100 U/ml penicillin,
and 100 mg/ml streptomycin) with different concentrations of the bile acids
TCA and TbMCA. The plates were then incubated overnight at 37C in 5%
CO2. The mixture containing the tissue was transferred to Eppendorf tubes
and centrifuged at 14,000 rpm for 5min. The tissuewas collected after removal
of the supernatant and used for analysis of mRNA expression.
Statistical Analysis
Values are expressed as mean ± SEM. Significant differences between two
groups were evaluated with a two-tailed, unpaired Student’s t test or Mann-
Whitney U test for samples that were not normally distributed. Multiple groups
were analyzed by one-way or two-way ANOVA followed by Bonferoni or
Dunnett’s multiple comparison test. PCA was performed with the Guineu soft-
ware for metabolomics data analysis, version 0.8 (Castelo and Roverato,
2009). Construction of the association network of tissues based on bile acid
profiles was performed with undirected Gaussian graphical Markov networks
that represent q-order partial correlations between variables, implemented in
an R package ‘‘qpgraph’’ (Castillo et al., 2011). In these networks, missing
edges denote zero partial correlations between pairs of variables and thus
imply the conditional independence relationships in the Gaussian case. The
network was visualized with Cytoscape (Cline et al., 2007).
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